Podcasts about Roll call

Kentucky Roll Call 08 - 09 - 22 by Kentucky Roll Call

Kentucky Roll Call 08 - 08 - 22 by Kentucky Roll Call

Kentucky Roll Call 08 - 05 - 22 by Kentucky Roll Call

Kentucky Roll Call 08 - 04 - 22 by Kentucky Roll Call

The Democrats' social spending and tax bill might get thwarted by another issue in the reconciliation process: Immigration. Roll Call's Caroline Simon has details on the Republicans' plan to use the often-contentious issue to put Democrats in a tough spot ahead of the midterms. See omnystudio.com/listener for privacy information.

Kentucky Roll Call 08 - 03 - 22 by Kentucky Roll Call

Kentucky Roll Call 08 - 02 - 22 by Kentucky Roll Call

In this episode of the Church Security Roll Call, we're going to be discussing the 2017 St. Alphonsus Church Shooting. Weekly Show Notes: https://sheepdog-church-security.ck.page/weekly-notes (Only Available for One Week after Show Goes Live) - AND - Church Shooting Lessons Learned Download: https://sheepdog-church-security.ck.page/lessons-learned (Changes Monthly) - About our Company - Sheepdog Church Security is a Private Online Academy that provides both Distance and Self-Paced Learning to Safety Team Volunteers. Our training focuses on Routine Safety and Security Operations and Emergency Situations in Houses of Worship. Links below to learn more about us and the online training we offer! Official Website: https://sheepdogchurchsecurity.net/ Training Academy: https://sheepdog-church-security.thinkific.com/ - Sheepdog Supporters - Worship Security Association: https://worshipsecurity.vhx.tv/?code=sheepdog Protect My Ministry: https://www.protectmyministry.com/sheepdog-signup/ U.S. Law Shield: https://www.uslawshield.com/?affid=f83659a7-c044-11e9-a753-02fcb63ac2fe The Cornelius Project: https://thecorneliusproject.com/ - Follow us on Social Media - Facebook: https://www.facebook.com/Instructor.Moloney/ Linkedin: https://www.linkedin.com/company/sheepdog-church-security - Contacts for Business Inquiries - Contact Us: https://sheepdogchurchsecurity.net/contact-us/

** Start at www.OnTheBlueLine.com for the complete show notes to each episode.    On The Blue Line Podcast | MORNING ROLL CALL | We're Back! | Episode 073 The On The Blue Line Podcast and Blog has the mission of Empowering Cops in their personal lives and educating the public on the realities of law enforcement. The morning roll call is a weekly monologue show with Wayne Mulder. The Interview Room podcast is an interview style format hosted by Wayne Mulder   In this episode:   Wayne talks about his experience in law enforcement, teaching at a law enforcement academy and what led him to starting the On The Blue Line in 2019. Wayne talks about the mission of On The Blue Line and how it affects everyone serving on the Thin Blue Line. Wayne discusses a Fox News Article titled, “Minnesota's City of Morris to disband police department” and goes over the lack of new police officers entering the law enforcement profession. Wayne discusses how Law Enforcement is the line between civility and anarchy. Wayne discusses how Law Enforcement is the face of both the community and the government. Wayne discusses how Law Enforcement is the last line of defense for the Constitution.   LINKS: Get the eBook, “How the law enforcement career makes you cynical and what you can do about it” by Wayne Mulder.

Kentucky Roll Call 08 - 01 - 22 by Kentucky Roll Call

Kentucky Roll Call 07 - 29 - 22 by Kentucky Roll Call

Kentucky Roll Call 07 - 28 - 22 by Kentucky Roll Call

Kentucky Roll Call 07 - 27 - 22 by Kentucky Roll Call

The Mariners win again and we celebrate Carlos Santana! Training Camp gets underway today, we review the big storylines. It's Fantasy Camp: Roll Call time!

Kentucky Roll Call 07 - 26 - 22 by Kentucky Roll Call

Staff Sgt. Kyle Keasey talks to us about his military career, including switching over to become a boomer in 108th Air Refueling Squadron. The Illinois Air National Guard headed to Toledo this weekend find out how they placed in the latest edition of Roll Call. Suicide Prevention Lifeline can now be reached at 988, Military press 1. https://suicidepreventionlifeline.org/ Text: HELP to 838255 Personal Financial Counselors: Drew Weckbach – 314-307-3300 pfc.mo.nosc@zeiders.com (off base - available during the week & drill by request) Jonathan Bracewell – 618-304-7311 pfc.scott.usaf@zeiders.com (located on base M-F, available for drill by request) Pain Free Running Clinic registration: heather.l.braundmeier.civ@mail.mil

In this episode of the Church Security Roll Call, we're going to be discussing Hurricane Safety. Weekly Show Notes: https://sheepdog-church-security.ck.page/weekly-notes (Only Available for One Week after Show Goes Live) - AND - Church Shooting Lessons Learned Download: https://sheepdog-church-security.ck.page/lessons-learned (Changes Monthly) - About our Company - Sheepdog Church Security is a Private Online Academy that provides both Distance and Self-Paced Learning to Safety Team Volunteers. Our training focuses on Routine Safety and Security Operations and Emergency Situations in Houses of Worship. Links below to learn more about us and the online training we offer! Official Website: https://sheepdogchurchsecurity.net/ Training Academy: https://sheepdog-church-security.thinkific.com/ - Sheepdog Supporters - Worship Security Association: https://worshipsecurity.vhx.tv/?code=sheepdog Protect My Ministry: https://www.protectmyministry.com/sheepdog-signup/ U.S. Law Shield: https://www.uslawshield.com/?affid=f83659a7-c044-11e9-a753-02fcb63ac2fe The Cornelius Project: https://thecorneliusproject.com/ - Follow us on Social Media - Facebook: https://www.facebook.com/Instructor.Moloney/ Linkedin: https://www.linkedin.com/company/sheepdog-church-security - Contacts for Business Inquiries - Contact Us: https://sheepdogchurchsecurity.net/contact-us/

Kentucky Roll Call 07 - 25 - 22 by Kentucky Roll Call

Kentucky Roll Call 07 - 22 - 22 by Kentucky Roll Call

Kentucky Roll Call 07 - 21 - 22 by Kentucky Roll Call

Kentucky Roll Call 07 - 20 - 22 by Kentucky Roll Call

This is Garrison Hardie with your CrossPolitic Daily News Brief for Tuesday, July 19th, 2022. Before we jump into the news for today, I have a question for you! Plug #1: Gold River Trading Co. Are you tired of buying sugary drinks and coffee from large woke corporations? Throw a tea party! Gold River Trading Co. is an American company that offers premium alternatives for Americans who enjoy a delicious cup of tea. Start your day with Gold River’s invigorating American Breakfast Blend, cool down with a pitcher of crisp & refreshing Iced Tea, or unwind with Chamomile Herbal tea. Explore a variety of high-quality blends and enjoy a healthy, flavorful alternative from an American company that shares your values. Go to goldriverco.com and save 10% off all orders using discount code CROSSPOLITIC at checkout. Now, let’s get to the news, starting with Dr. Anthony Fauci! https://www.theepochtimes.com/fauci-reveals-exactly-when-hes-leaving-the-federal-government_4604550.html?utm_source=partner&utm_campaign=BonginoReport Fauci Reveals Exactly When He’s Leaving the Federal Government White House COVID-19 adviser Anthony Fauci revealed that after about five decades in the federal government, he’s planning on leaving his position by the end of President Joe Biden’s term. “We’re in a pattern now. If somebody says, ‘You’ll leave when we don’t have COVID anymore,’ then I will be 105. I think we’re going to be living with this,” Fauci, 81, told Politico in an interview published on Monday morning in confirming he’s retiring at the end of Biden’s term in office, which is Jan. 21, 2025. Fauci has been the head of the National Institute of Allergy and Infectious Diseases (NIAID) since 1984. During the COVID-19, he became a household name when he became the face of the federal government’s COVID-19 pandemic response, often generating criticism from Republicans and conservatives about his generally dire predictions about the pandemic. Of his relationship with former President Donald Trump, Fauci said that “we developed an interesting relationship … two guys from New York, different in their opinions and their ideology, but still, two guys who grew up in the same environments of this city. I think that we are related to each other in that regard.” And if Republicans win back either the House or Senate in 2022, Fauci noted that he will likely be investigated by GOP lawmakers. But he claimed that regarding those investigations, “I don’t make that a consideration in my career decision.” However, Fauci has faced public questions from Republicans in Congress about his agency having given funding to third-party groups to carry out research in China. COVID-19, caused by the CCP (Chinese Communist Party) virus, emerged in Wuhan, China, and a significant number of U.S. intelligence officials last year released a report suggesting the virus may be tied to the top-level Wuhan Institute of Virology. Last month, amid questions from Sen. Roger Marshall (R-Kan.), Fauci admitted that he is not able to halt federal funding from being doled out to researchers in China. “The NIH [National Institutes of Health] is still funding research in China, at least $8 million since 2020,” Marshall said. “In the Intelligence Community’s 2022 Annual Threat Assessment, the Chinese Communist Party is presented as one of the top threats to the United States, along with Russia, Iran, Syria, and North Korea. To my knowledge, only China is receiving U.S. research dollars.” Later, he asked Fauci, “When will you as director of NIAID stop funding research in China?” Federal health agencies, Fauci said in response, “had very productive peer-reviewed highly regarded research projects with our Chinese colleagues that have led to some major advances in biomedical research.” “We obviously need to be careful and make sure that when we do fund them we have the proper peer review and we go through all the established guidelines,” he also said. https://dailycaller.com/2022/07/17/shameful-biden-admin-sold-6-million-barrels-strategic-oil-reserves-china/ Biden Admin Has Sold Nearly 6 Million Barrels Of Strategic Oil Reserves To China The Biden administration sold nearly six million barrels of oil from its Strategic Petroleum Reserve (SPR) since July 2021 to a Chinese state-run energy firm, according to a Daily Caller News Foundation review of Department of Energy (DOE) data. From July 2021 until the end of June 2022, Biden’s energy department auctioned off 5.9 million barrels of strategic reserve oil to Unipec, the trading division of the Chinese state-owned Sinopec, in an effort to increase the supply of oil globally and drive down fuel costs in the U.S. that were exacerbated by the war in Ukraine and Biden’s climate policies. SPR oil is sold to the highest bidder, and some of the businesses entitled to make bids are American subsidiaries of foreign corporations like Unipec The DOE sold four million barrels to Unipec in the fall of 2021, almost six months before Russia’s invasion of Ukraine, making over $252 million from the sale, according to the FY22 Emergency Drawdown No. 2 Successful Awards Report. Each barrel was sold on average for roughly $63, or over eight dollars less than the average price of oil per barrel that month. “I think it takes a bad policy and makes it worse,” Ben Lieberman, a senior fellow at the Competitive Enterprise Institute, told the Daily Caller News Foundation. In July 2022 the DOE sold 950,000 barrels to Unipec for roughly $113 million, according to the FY22 Emergency Drawdown No. 3A Successful Awards Report. While the Biden administration claimed the sales will help the U.S. fight “Putin’s price hike,” Unipec is still buying large quantities of Russian oil, according to Bloomberg. “It’s helping out a bit, but it’s still a very bad policy,” Lieberman told the DCNF. “The fact that we’re using the Strategic Petroleum Reserve rather than drilling offshore or getting more oil to the United States through the Keystone XL pipeline, the fact that we’re not doing these things is really pretty shameful.” In April, the DOE also sold 950,000 barrels to Unipec, according to a DOE report. “The Strategic Petroleum Reserve never really was a substitute for that and now to hear that this oil is going to China is problematic because it undercuts their rationale even more,” said Lieberman. “Biden’s policy just shows that he’s not putting American consumers and the American economy first or second or even third.” The DOE, the White House and Sinopec did not respond to the DCNF’s request for comment. Plug #2: Armored Republic The Mission of Armored Republic is to Honor Christ by equipping Free Men with Tools of Liberty necessary to preserve God-given rights. In the Armored Republic there is no King but Christ. We are Free Craftsmen. Body Armor is a Tool of Liberty. We create Tools of Liberty. Free men must remain ever vigilant against tyranny wherever it appears. God has given us the tools of liberty needed to defend the rights He bestowed to us. Armored Republic is honored to offer you those Tools. Visit them, at ar500armor.com https://www.theepochtimes.com/congress-grants-pentagon-58-billion-more-than-requested-dod-report_4603312.html?utm_source=partner&utm_campaign=BonginoReport Congress Grants Pentagon $58 Billion More Than Requested: DOD Report US lawmakers granted the Department of Defense (DOD) more money than the Pentagon requested for in the fiscal 2022 defense budget, a recent Pentagon report shows. In total, Congress sanctioned $58.55 billion in additional funds, according to the report. This includes $25.70 billion for operations and maintenance, $17.67 billion for procurement, $9.89 billion for research, development, test, and evaluation, $4.32 billion for military construction, and $947 million for military personnel. The DOD initially had a base budget appropriation of $742.3 billion for fiscal 2022. As such, the extra $58.55 billion represents an almost 8 percent increase from the base budget. The Pentagon did not put in a request for any of the programs funded with the extra $58.55 billion. These programs are not even in the so-called unfunded priorities lists—made up of items not included in the budget but considered critical—that departments and officers send to Congress annually. For instance, roughly $4 billion was granted for half a dozen ships that were not on the unfunded priorities list. Similarly, the Navy received $900 million for a dozen Super Hornet jets, the Air National Guard got $1.8 billion to purchase 16 C-130J transport planes, and $460 million was granted for developing advanced jet engines. Over $2 billion in extra funds was appropriated for classified programs. The $58.55 billion calculation only takes into account individual additions totaling $20 million or more. Since there are usually many spending hikes in the single-digit millions, the total actual excess funding will likely be higher. In an email to Roll Call, Steve Ellis, president of Taxpayers for Common Sense, a government spending watchdog group, called for more efficient military budgets. “Certainly Congress has the power of the purse, but considering the Pentagon got more than $750 billion that year, lawmakers could work within that generous budget to reflect their priorities … Instead, they dumped more than $50 billion across accounts for what appear to be in some cases very parochial interests.” Since fiscal 2017, the Pentagon’s base budget has risen by 48 percent. The recently passed House version of the 2023 defense budget ups the funding received by the Pentagon, authorizing $839 billion in military spending—$37 billion more than was requested by the administration. And now, it’s time for the topic that I love… sports! You all know we’re on the Fight Laugh Feast Network, so now let’s talk about some fighting… https://nypost.com/2022/07/17/bronx-native-shane-burgos-now-7-0-in-ufc-bouts-in-new-york/ Bronx native Shane Burgos now 7-0 in UFC bouts in New York Shane Burgos’ record remains perfect in the Empire State. He can thank one hell of a chin for that. The Bronx native, who expressed displeasure with his performance, nevertheless managed to hold on for a majority decision victory over Charles Jourdain on Saturday at UBS Arena in featherweight action during the UFC’s first Long Island event in five years. The win moved him to 7-0 in UFC bouts in his home state. Shane Burgos hates how he ended the fight against Charles Jourdain | ESPN MMA - Play 2:25-3:52 Fans anticipated a clash of action-oriented strikers entering the main-card bout. But for two rounds, Burgos was a grappling beast and Jourdain simply couldn’t handle him. Burgos and his Tiger Schulmann’s MMA team anticipated that strategy would work. In a nifty moment early on, Burgos pushed off the octagon to help secure Jourdain’s back and to attack a rear-naked choke from the body triangle in the highest spot of the first round. He took the back with a standing body triangle again the following round, keeping it longer this time. The expected war on the feet broke out in the final round, but the battle was largely one-way traffic. Jourdain cracked Burgos often, besting the local favorite in significant strikes 84-26, per UFC Stats. Now let’s check in on some baseball standings, as I’m sure we’ve got some baseball fans in our audience: Starting in the American League AL East: The New York Yankees are firing on all cylinders, with a 64-28 record, leading all clubs across the Majors as far as best record goes. The second closest record in the AL East goes to the Tampa Bay Rays, a full-13 games back. It’s a close race in the AL Central, as the Minnesotta Twins are leading the way with a 50-44 record, and two teams are nipping at their heels. The Cleveland Guardians, or Indians as I’ll continue to call them, are standing at 46-44. While the Chicago Whitesox sit at 46-46. In the AL West, it’s a two team race featuring the Houston Astros, and the surprisingly hot Seattle Mariners! The Astros sit at 59-32, and the Mariners are 51-42. By the way, the Mariners are on a 14-game winning streak, and on top of that, the Astros and Mariners have a three game series starting this Friday! Over to the National League, the Mets & the Braves are separated by 2.5 games atop the east. In the NL Central, the Brewers are only ahead of the Cardinals by half a game. Each of them have 50 wins a piece. And finally, in the NL West, the Dodgers lead the way with the second best record in baseball, at 60-30. That’s your look at sports, and this has been your CrossPolitic Daily News Brief. If you liked this show, go ahead and hit that share button for me would ya? If you want to sign up for a club membership, a magazine subscription, or sign up for our conference in Knoxville TN, you need to head over to fightlaughfeast.com, and sign up there. And as always, if you’d like to become a corporate partner with CrossPolitic, email me, at garrison@fightlaughfeast.com. For CrossPolitic News, I’m Garrison Hardie. Have a great rest of your day, and Lord bless.

This is Garrison Hardie with your CrossPolitic Daily News Brief for Tuesday, July 19th, 2022. Before we jump into the news for today, I have a question for you! Plug #1: Gold River Trading Co. Are you tired of buying sugary drinks and coffee from large woke corporations? Throw a tea party! Gold River Trading Co. is an American company that offers premium alternatives for Americans who enjoy a delicious cup of tea. Start your day with Gold River’s invigorating American Breakfast Blend, cool down with a pitcher of crisp & refreshing Iced Tea, or unwind with Chamomile Herbal tea. Explore a variety of high-quality blends and enjoy a healthy, flavorful alternative from an American company that shares your values. Go to goldriverco.com and save 10% off all orders using discount code CROSSPOLITIC at checkout. Now, let’s get to the news, starting with Dr. Anthony Fauci! https://www.theepochtimes.com/fauci-reveals-exactly-when-hes-leaving-the-federal-government_4604550.html?utm_source=partner&utm_campaign=BonginoReport Fauci Reveals Exactly When He’s Leaving the Federal Government White House COVID-19 adviser Anthony Fauci revealed that after about five decades in the federal government, he’s planning on leaving his position by the end of President Joe Biden’s term. “We’re in a pattern now. If somebody says, ‘You’ll leave when we don’t have COVID anymore,’ then I will be 105. I think we’re going to be living with this,” Fauci, 81, told Politico in an interview published on Monday morning in confirming he’s retiring at the end of Biden’s term in office, which is Jan. 21, 2025. Fauci has been the head of the National Institute of Allergy and Infectious Diseases (NIAID) since 1984. During the COVID-19, he became a household name when he became the face of the federal government’s COVID-19 pandemic response, often generating criticism from Republicans and conservatives about his generally dire predictions about the pandemic. Of his relationship with former President Donald Trump, Fauci said that “we developed an interesting relationship … two guys from New York, different in their opinions and their ideology, but still, two guys who grew up in the same environments of this city. I think that we are related to each other in that regard.” And if Republicans win back either the House or Senate in 2022, Fauci noted that he will likely be investigated by GOP lawmakers. But he claimed that regarding those investigations, “I don’t make that a consideration in my career decision.” However, Fauci has faced public questions from Republicans in Congress about his agency having given funding to third-party groups to carry out research in China. COVID-19, caused by the CCP (Chinese Communist Party) virus, emerged in Wuhan, China, and a significant number of U.S. intelligence officials last year released a report suggesting the virus may be tied to the top-level Wuhan Institute of Virology. Last month, amid questions from Sen. Roger Marshall (R-Kan.), Fauci admitted that he is not able to halt federal funding from being doled out to researchers in China. “The NIH [National Institutes of Health] is still funding research in China, at least $8 million since 2020,” Marshall said. “In the Intelligence Community’s 2022 Annual Threat Assessment, the Chinese Communist Party is presented as one of the top threats to the United States, along with Russia, Iran, Syria, and North Korea. To my knowledge, only China is receiving U.S. research dollars.” Later, he asked Fauci, “When will you as director of NIAID stop funding research in China?” Federal health agencies, Fauci said in response, “had very productive peer-reviewed highly regarded research projects with our Chinese colleagues that have led to some major advances in biomedical research.” “We obviously need to be careful and make sure that when we do fund them we have the proper peer review and we go through all the established guidelines,” he also said. https://dailycaller.com/2022/07/17/shameful-biden-admin-sold-6-million-barrels-strategic-oil-reserves-china/ Biden Admin Has Sold Nearly 6 Million Barrels Of Strategic Oil Reserves To China The Biden administration sold nearly six million barrels of oil from its Strategic Petroleum Reserve (SPR) since July 2021 to a Chinese state-run energy firm, according to a Daily Caller News Foundation review of Department of Energy (DOE) data. From July 2021 until the end of June 2022, Biden’s energy department auctioned off 5.9 million barrels of strategic reserve oil to Unipec, the trading division of the Chinese state-owned Sinopec, in an effort to increase the supply of oil globally and drive down fuel costs in the U.S. that were exacerbated by the war in Ukraine and Biden’s climate policies. SPR oil is sold to the highest bidder, and some of the businesses entitled to make bids are American subsidiaries of foreign corporations like Unipec The DOE sold four million barrels to Unipec in the fall of 2021, almost six months before Russia’s invasion of Ukraine, making over $252 million from the sale, according to the FY22 Emergency Drawdown No. 2 Successful Awards Report. Each barrel was sold on average for roughly $63, or over eight dollars less than the average price of oil per barrel that month. “I think it takes a bad policy and makes it worse,” Ben Lieberman, a senior fellow at the Competitive Enterprise Institute, told the Daily Caller News Foundation. In July 2022 the DOE sold 950,000 barrels to Unipec for roughly $113 million, according to the FY22 Emergency Drawdown No. 3A Successful Awards Report. While the Biden administration claimed the sales will help the U.S. fight “Putin’s price hike,” Unipec is still buying large quantities of Russian oil, according to Bloomberg. “It’s helping out a bit, but it’s still a very bad policy,” Lieberman told the DCNF. “The fact that we’re using the Strategic Petroleum Reserve rather than drilling offshore or getting more oil to the United States through the Keystone XL pipeline, the fact that we’re not doing these things is really pretty shameful.” In April, the DOE also sold 950,000 barrels to Unipec, according to a DOE report. “The Strategic Petroleum Reserve never really was a substitute for that and now to hear that this oil is going to China is problematic because it undercuts their rationale even more,” said Lieberman. “Biden’s policy just shows that he’s not putting American consumers and the American economy first or second or even third.” The DOE, the White House and Sinopec did not respond to the DCNF’s request for comment. Plug #2: Armored Republic The Mission of Armored Republic is to Honor Christ by equipping Free Men with Tools of Liberty necessary to preserve God-given rights. In the Armored Republic there is no King but Christ. We are Free Craftsmen. Body Armor is a Tool of Liberty. We create Tools of Liberty. Free men must remain ever vigilant against tyranny wherever it appears. God has given us the tools of liberty needed to defend the rights He bestowed to us. Armored Republic is honored to offer you those Tools. Visit them, at ar500armor.com https://www.theepochtimes.com/congress-grants-pentagon-58-billion-more-than-requested-dod-report_4603312.html?utm_source=partner&utm_campaign=BonginoReport Congress Grants Pentagon $58 Billion More Than Requested: DOD Report US lawmakers granted the Department of Defense (DOD) more money than the Pentagon requested for in the fiscal 2022 defense budget, a recent Pentagon report shows. In total, Congress sanctioned $58.55 billion in additional funds, according to the report. This includes $25.70 billion for operations and maintenance, $17.67 billion for procurement, $9.89 billion for research, development, test, and evaluation, $4.32 billion for military construction, and $947 million for military personnel. The DOD initially had a base budget appropriation of $742.3 billion for fiscal 2022. As such, the extra $58.55 billion represents an almost 8 percent increase from the base budget. The Pentagon did not put in a request for any of the programs funded with the extra $58.55 billion. These programs are not even in the so-called unfunded priorities lists—made up of items not included in the budget but considered critical—that departments and officers send to Congress annually. For instance, roughly $4 billion was granted for half a dozen ships that were not on the unfunded priorities list. Similarly, the Navy received $900 million for a dozen Super Hornet jets, the Air National Guard got $1.8 billion to purchase 16 C-130J transport planes, and $460 million was granted for developing advanced jet engines. Over $2 billion in extra funds was appropriated for classified programs. The $58.55 billion calculation only takes into account individual additions totaling $20 million or more. Since there are usually many spending hikes in the single-digit millions, the total actual excess funding will likely be higher. In an email to Roll Call, Steve Ellis, president of Taxpayers for Common Sense, a government spending watchdog group, called for more efficient military budgets. “Certainly Congress has the power of the purse, but considering the Pentagon got more than $750 billion that year, lawmakers could work within that generous budget to reflect their priorities … Instead, they dumped more than $50 billion across accounts for what appear to be in some cases very parochial interests.” Since fiscal 2017, the Pentagon’s base budget has risen by 48 percent. The recently passed House version of the 2023 defense budget ups the funding received by the Pentagon, authorizing $839 billion in military spending—$37 billion more than was requested by the administration. And now, it’s time for the topic that I love… sports! You all know we’re on the Fight Laugh Feast Network, so now let’s talk about some fighting… https://nypost.com/2022/07/17/bronx-native-shane-burgos-now-7-0-in-ufc-bouts-in-new-york/ Bronx native Shane Burgos now 7-0 in UFC bouts in New York Shane Burgos’ record remains perfect in the Empire State. He can thank one hell of a chin for that. The Bronx native, who expressed displeasure with his performance, nevertheless managed to hold on for a majority decision victory over Charles Jourdain on Saturday at UBS Arena in featherweight action during the UFC’s first Long Island event in five years. The win moved him to 7-0 in UFC bouts in his home state. Shane Burgos hates how he ended the fight against Charles Jourdain | ESPN MMA - Play 2:25-3:52 Fans anticipated a clash of action-oriented strikers entering the main-card bout. But for two rounds, Burgos was a grappling beast and Jourdain simply couldn’t handle him. Burgos and his Tiger Schulmann’s MMA team anticipated that strategy would work. In a nifty moment early on, Burgos pushed off the octagon to help secure Jourdain’s back and to attack a rear-naked choke from the body triangle in the highest spot of the first round. He took the back with a standing body triangle again the following round, keeping it longer this time. The expected war on the feet broke out in the final round, but the battle was largely one-way traffic. Jourdain cracked Burgos often, besting the local favorite in significant strikes 84-26, per UFC Stats. Now let’s check in on some baseball standings, as I’m sure we’ve got some baseball fans in our audience: Starting in the American League AL East: The New York Yankees are firing on all cylinders, with a 64-28 record, leading all clubs across the Majors as far as best record goes. The second closest record in the AL East goes to the Tampa Bay Rays, a full-13 games back. It’s a close race in the AL Central, as the Minnesotta Twins are leading the way with a 50-44 record, and two teams are nipping at their heels. The Cleveland Guardians, or Indians as I’ll continue to call them, are standing at 46-44. While the Chicago Whitesox sit at 46-46. In the AL West, it’s a two team race featuring the Houston Astros, and the surprisingly hot Seattle Mariners! The Astros sit at 59-32, and the Mariners are 51-42. By the way, the Mariners are on a 14-game winning streak, and on top of that, the Astros and Mariners have a three game series starting this Friday! Over to the National League, the Mets & the Braves are separated by 2.5 games atop the east. In the NL Central, the Brewers are only ahead of the Cardinals by half a game. Each of them have 50 wins a piece. And finally, in the NL West, the Dodgers lead the way with the second best record in baseball, at 60-30. That’s your look at sports, and this has been your CrossPolitic Daily News Brief. If you liked this show, go ahead and hit that share button for me would ya? If you want to sign up for a club membership, a magazine subscription, or sign up for our conference in Knoxville TN, you need to head over to fightlaughfeast.com, and sign up there. And as always, if you’d like to become a corporate partner with CrossPolitic, email me, at garrison@fightlaughfeast.com. For CrossPolitic News, I’m Garrison Hardie. Have a great rest of your day, and Lord bless.

Kentucky Roll Call 07 - 19 - 22 by Kentucky Roll Call

Hi, thanks for watching our videos about the Silverback Chronicles Podcast! In this video we'll walk you through: Latest concerns and answer questions bout some of the hot news stories. ABOUT OUR CHANNEL Our channel is about 2 NY born Detectives bridging the gap all walks of life. We cover lots of interesting topics such as our lives, patrol and unique careers. Check out our channel here: https://www.youtube.com/silverbackchronicles Don't forget to subscribe! CHECK OUT OUR OTHER VIDEOS https://www.youtube.com/silverbackchronicles We sell these awesome products, check them out here: https://www.silverback chronicles.com FIND US AT https://www.silverback chronicles.com GET IN TOUCH Contact us on Silverback Chronicles Podcast FOLLOW US ON SOCIAL Get updates or reach out to Get updates on our Social Media Profiles! Twitter: https://twitter.com/silverbackpod Facebook: https://facebook.com/silverbackpod Instagram: https://twitter.com/silverbackpod Spotify: http://spotify.com/66kD3pI5vu2fMVjSk5GOYz --- Send in a voice message: https://anchor.fm/silverbackchronicles/message Support this podcast: https://anchor.fm/silverbackchronicles/support

In this episode of the Church Security Roll Call, we're going to be discussing Identifying Sexual Offenders. Weekly Show Notes: https://sheepdog-church-security.ck.page/weekly-notes (Only Available for One Week after Show Goes Live) - AND - Church Shooting Lessons Learned Download: https://sheepdog-church-security.ck.page/lessons-learned (Changes Monthly) - About our Company - Sheepdog Church Security is a Private Online Academy that provides both Distance and Self-Paced Learning to Safety Team Volunteers. Our training focuses on Routine Safety and Security Operations and Emergency Situations in Houses of Worship. Links below to learn more about us and the online training we offer! Official Website: https://sheepdogchurchsecurity.net/ Training Academy: https://sheepdog-church-security.thinkific.com/ - Sheepdog Supporters - Worship Security Association: https://worshipsecurity.vhx.tv/?code=sheepdog Protect My Ministry: https://www.protectmyministry.com/sheepdog-signup/ U.S. Law Shield: https://www.uslawshield.com/?affid=f83659a7-c044-11e9-a753-02fcb63ac2fe The Cornelius Project: https://thecorneliusproject.com/ - Follow us on Social Media - Facebook: https://www.facebook.com/Instructor.Moloney/ Linkedin: https://www.linkedin.com/company/sheepdog-church-security - Contacts for Business Inquiries - Contact Us: https://sheepdogchurchsecurity.net/contact-us/

Kentucky Roll Call 07 - 18 - 22 by Kentucky Roll Call

The recently signed gun law, S. 2938: Bipartisan Safer Communities Act, contained a surprise dingleberry postponing a regulation designed to save seniors money on their pharmaceutical drugs by prohibiting kickbacks to an industry few have heard of: Pharmacy Benefit Managers (PBMs). This little-known but extremely powerful industry deserves much of the blame for ever rising prescription drugs costs in the United States. In this episode, Jen gives you the scoop on PBMs and how they make their money at the expense of Americans who are most dependent on medications. Please Support Congressional Dish – Quick Links Contribute monthly or a lump sum via PayPal Support Congressional Dish via Patreon (donations per episode) Send Zelle payments to: Donation@congressionaldish.com Send Venmo payments to: @Jennifer-Briney Send Cash App payments to: $CongressionalDish or Donation@congressionaldish.com Use your bank's online bill pay function to mail contributions to: 5753 Hwy 85 North, Number 4576, Crestview, FL 32536. Please make checks payable to Congressional Dish Thank you for supporting truly independent media! View the shownotes on our website at https://congressionaldish.com/cd255-pharmacy-benefit-managers-pbms We're Not Wrong Berlin Meetup Contact Justin at WereNotWrongPod@gmail.com Background Sources Recommended Congressional Dish Episodes CD134: The EpiPen Hearing US Healthcare Landscape Jessi Jezewska Stevens. Apr 23, 2020. “A Brief History of the Great American Healthcare Scam.” Bookforum. Tanza Loudenback. Mar 7, 2019. “The average cost of healthcare in 21 different countries.” Insider. Chuck Grassley and Ron Wyden. 2019. “Insulin: Examining the Factors Driving the Rising Cost of a Century Old Drug [Staff Report].” U.S. Senate Finance Committee. “Health Insurance Coverage of the Total Population.” Kaiser Family Foundation. Sara R. Collins and David C. Radley. Dec 7, 2018. “The Cost of Employer Insurance Is a Growing Burden for Middle-Income Families.” The Commonwealth Fund. PBMs What are PBMs? JC Scott. Jun 30, 2022. “Drug manufacturers are root cause of high drug costs; PBMs drive costs down.” The Hill. Zach Freed. Jun 22, 2022. “The Pharmacy Benefit Mafia: The Secret Health Care Monopolies Jacking Up Drug Prices and Abusing Patients and Pharmacists.” American Economic Liberties Project. Adam J. Fein. Jun 22, 2021. “The Top Pharmacy Benefit Managers of 2020: Vertical Integration Drives Consolidation (rerun).” Drug Channels. “Flash finding: How drug money from sick people really works.” Nov 11, 2021. 46brooklyn. Adam J. Fein. Feb 3, 2019. “Don't Blame Drug Prices on ‘Big Pharma.'” The Wall Street Journal. How PBMs Make Money “DIR Fees.” National Association of Chain Drug Stores. “How PBMs Make Money: PBM Practices & Profits.” RxSafe. True North Political Solutions. Oct 25, 2017. “White Paper: DIR Fees Simply Explained.” Pharmacy Times. ACA “Vertical Integration” Loophole Peter High. Jul 8, 2019. “A View From Inside Cigna's $67 Billion Acquisition Of Express Scripts.” Forbes. Angelica LaVito. Nov 28, 2018. “CVS creates new health-care giant as $69 billion merger with Aetna officially closes.” CNBC. David Dayen. Oct 12, 2018. “Why the Aetna and CVS Merger Is So Dangerous.” The American Prospect. Jeff Byers. April 12, 2018. “Optum a step ahead in vertical integration frenzy.” Healthcare Dive. Graph: Optum opens up wider market for UnitedHealth Group Graph: Optum's pharmacy business contributes the majority of its revenue Susan Morse. May 10, 2017. “Secret weapon: UnitedHealth's Optum business is laying waste to old notions about how payers make money.” Healthcare Finance. Lobbying “Client Profile: Pharmaceutical Care Management Assn.” Open Secrets. The Demise of Independent Pharmacies Christine Blank. Oct 17, 2019. “Independents Prepare to Close Up Shop.” Drug Topics. Paulina Firozi. Aug 23, 2018. “The Health 202: Here's why rural independent pharmacies are closing their doors.” The Washington Post. What Is a Formulary? Ana Gascon Ivey. May 19, 2020. “A Guide to Medication Formularies.” GoodRx. Previous Delays in Rebate Regulation Paige Minemyer. Jan 29, 2021. “In a win for PBMs, Biden administration delays rebate rule.” Fierce Healthcare. Paige Minemyer. Jan 12, 2021. “PCMA sues Trump administration over rebate rule.” Fierce Healthcare. “Incorporating the Effects of the Proposed Rule on Safe Harbors for Pharmaceutical Rebates in CBO's Budget Projections—Supplemental Material for Updated Budget Projections: 2019 to 2029.” May 2019. Congressional Budget Office. The Gun Law Passage Process Office of the Clerk. May 18, 2022. “Roll Call 212 | Bill Number: S. 2938.” U.S. House of Representatives. Tampa Bay Times Editorial Board. May 12, 2022. “Republican lawmakers should be ashamed for failing to honor Justice Joseph Hatchett.” Miami Herald. Annie Karni. Apr 12, 2022. “House G.O.P., Banding Together, Kills Bid to Honor Pioneering Black Judge.” The New York Times. Background on Most Important Provisions Mary Katherine Wildeman. May 26, 2022. “Data show most school shootings carried out by young adults, teens.” CT Insider. Jeffrey Pierre. May 26, 2022. “Experts say we can prevent school shootings. Here's what the research says.” NPR. The Dingleberry Erik Sherman. Jun 30, 2022. “Gun Safety Bill Extends Drug Middlemen Protection From Anti-Kickback Measure.” Forbes. Molly Rutherford. Jun 28, 2022. “Gun legislation provision puts drug supply chain profits over patients.” The Hill. Marty Schladen. Jun 22, 2022. “Deep inside the gun bill: a break for prescription drug middlemen.” Iowa Capital Dispatch. Poland Train Station Taylor Popielarz, Maureen McManus and Justin Tasolides. Mar 25, 2022. “‘The help given is remarkable': Inside the Poland train station that's become a hub for Ukrainian refugees.” Spectrum News NY1. The Law and the Regulation S. 2938: Bipartisan Safer Communities Act Senate Vote: 65-33 (All Nos GOP) House Vote: 234-193 (All Nos GOP) Jen's Highlighted PDF of S. 2938: Bipartisan Safer Communities Act Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees U.S. Health and Human Services Department November 30, 2020 Audio Sources The State of Competition in the Pharmacy Benefits Manager and Pharmacy Marketplaces November 17, 2015 House Committee on the Judiciary Witnesses: Bradley J. Arthur, R.Ph., Owner, Black Rock Pharmacy David Balto, Law Offices of David A. Balto PLLC Amy Bricker, R.Ph. Vice President of Retail Contracting & Strategy, Express Scripts Natalie A. Pons, Senior Vice President and Assistant General Counsel, CVS Health Clips 53:48 Bradley Arthur: The Big Three PBMs control almost 80% of the entire market and these PBMs have the upper hand both in negotiating the contract with the payer, as well as strongly influencing the actual plan design itself. The PBM industry typically states that they can use their economic power to harness enhanced market efficiencies, but for whom? However, the staggering annual revenues that continue to grow each year of the big three suggests that these efficiencies are going directly to their corporations' bottom lines. Small community pharmacies like mine are faced on a daily basis with the impact of the PBMs' disproportionate market power. Community pharmacies routinely must agree to take-it-or-leave-it contracts from the PBMs just to continue to serve our long-standing patients. As if that weren't enough, the PBMs also directly set the reimbursement rates for pharmacies, the very same pharmacies that stand in direct competition of some of these PBM-owned mail-order and specialty pharmacies. Therefore, it comes as no surprise that the PBMs present employer and government payers with carefully tailored suggested plans designs that steer beneficiaries to these PBM-owned entities. Drug Pricing in America: A Prescription for Change, Part I January 29, 2019 Senate Committee on Finance Witnesses: Kathy Sego, Mother of a Child with Insulin-Dependent Diabetes Douglas Holtz-Eakin, Ph.D., President, American Action Forum Mark E. Miller, Ph.D., Vice President of Health Care, Laura and John Arnold Foundation Peter B. Bach, MD, MAPP, Director, Memorial Sloan Kettering Center for Health Policy and Outcomes Clips 1:57:30 Sen. John Cornyn (R - TX): Can anybody on the panel explain to me why we have a general prohibition against kickbacks — they call them rebates — under the Social Security Act, but we nevertheless allow it for prescription drug pricing? What's the sound public policy reason for excluding prescription drug pricing from the anti-kickback rule under federal law? Douglas Holtz-Eakin: I can't explain that and won't pretend to. [laughter] Sen. Cornyn: I thought I was the only one who didn't understand the wisdom of that. Well, it's not a transparent arrangement and it does produce upward pressure on drug prices. And obviously, the negotiations between the PBM and the pharma in terms of what the net cost is, is not transparent, nor is it delivered to the consumer. Is it Dr. Miller? Dr. Bach? Peter Bach: It's delivered to the consumer indirectly through the reduction of the total cost of the benefit, but it is not delivered to the actual consumer using the drug, and that is a disassociation, that is a problem. Because it essentially reverses the structure of insurance. Lowering the total costs are people who use it the least, and raising the costs are people who use it the most, relative to if you allowed the rebate to be used at the point of sale, including all discounts. 1:59:49 Douglas Holtz-Eakin: If we had the negotiation be about the upfront price, so instead of a high list price and a rebate, you just negotiate a lower price, that would be the price that Ms. Sego would pay and insurance companies would look at that and say, okay, she's not paying as much as she used to, we're going to have to make up that money somewhere else and they might raise premiums. That means that people who don't have extreme insulin drug costs would pay a little bit more in a premium every month, and people who have extremely devastating medical conditions and high health care costs would get less costs. That's exactly what insurance is supposed to do. And so the rebate system is more than giving strange incentives on pricing. It's undercutting the purpose of insurance in general. Drug Pricing in America: A Prescription for Change, Part II February 26, 2019 Senate Committee on Finance Witnesses: Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie Inc. Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Co. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals, Johnson & Johnson Kenneth C. Frazier, Chairman and Chief Executive Officer, Merck & Co., Inc. Albert Bourla, DVM, Ph.D., Chief Executive Office, Pfizer Olivier Brandicourt, M.D., Former Chief Executive Officer, Sanofi Clips 1:22:03 Albert Bourla: Adverse incentives that favor higher cost biologics are keeping biosimilars from reaching patients. In many cases, insurance companies declined to include lower cost biosimilars in their formularies because they would risk losing the rebates from covering higher cost medicines. I can't think of a more concerning example of a broken system and we need to do something about it. 1:33:35 Sen. Chuck Grassley (R - IA): So many of you have voiced support for the recent rebate rule proposed by the administration. Should the administration finalized this rule, will you commit to lowering your drug prices? Richard Gonzalez [CEO, AbbVie]: Mr. Chairman, we are supportive of the rule. We'd like to see it in its final form, obviously, to make a final decision, but we are supportive of taking the discount to the patient at the point of sale. Sen Grassley: Okay. AstraZeneca? **Pascal Soriot [CEO, AstraZeneca]**The same for us Senator, I would go one step further: if the rebates were removed from the commercial sector as well, we will definitely reduce our list prices. Sen Grassley: Okay. And Bristol? Giovanni Caforio [CEO, Bristol-Myers Squibb]: We have the same positions. Sen Grassley: Okay. Johnson and Johnson? Jennifer Taubert [EVP, J&J]: Yes, we're supportive, and that definitely would be my goal. We would just need to see the final legislation, provided that there aren't additional fees that are added into the system to compensate for the rebates. Sen Grassley: Merck? **Kenneth C. Frazier: I would expect that our prices would go down if we change the system. Again, on the commercial side as well as the Medicare side. Sen Grassley: Okay, Pfizer? Albert Bourla [CEO, Pfizer]: It is a very clear intention that we will not keep a single dollar from these rebates. We will try to move every single penny to the patients and we think if this goes also to the commercial plants that will be even better for more patients. Sen Grassley: Okay. Sanofi? Olivier Brandicourt [Former CEO, Sanofi]: Lowering list price has to be linked to better access and affordability at the counter for the patients. 1:35:20 Sen. Ron Wyden (D - OR): Is it correct that your company, and nobody else, sets the starting price for all drugs sold by Pfizer? Yes or no? Albert Bourla: It is a negotiation with PBMs and they are very powerful. Sen. Wyden: But you still get to set the list price? Albert Bourla: Yes, but we set this price and the rebate limit(?). 1:35:40 Sen. Ron Wyden (D - OR): Is it correct, when a hypothetical patient, let's call her Mrs. Jones, goes to pay for her drug at the pharmacy counter, her coinsurance is based on the price of the drug you set? Albert Bourla: It is correct in many cases. Sen. Wyden: Okay. I just want you all to know that the number one reason consumers are getting hammered, is because these list prices, which you have the last word with respect to where they are, are unaffordable. And the high prices are tied to what the consumer pays at the pharmacy counter. And all this other stuff you talk about, the rebates and the discounts and the coupons, all this other stuff is window dressing, all of that. And the fact is on Part D, 40% of the drugs don't even have a rebate. So I want it understood, particularly because I've asked you, Mr. Borla, I think you and others in the industry are stonewalling on the key issue, which is actually lowering list prices. And reducing those list prices are the easiest way for American consumers to pay less at the pharmacy counter. 2:12:45 Sen. Thomas Carper (D-DE): First is eliminating rebates to PBMs. That's the first one, eliminating rebates to PBMs. The second is value based arrangements. And the third is increasing transparency industry-wide on how you set your prices. 2:13:20 Richard Gonzalez: We clearly support providing the discount at the patient level, eliminating rebates essentially. 2:14:10 Pascal Soriot: If the rebates, as I said earlier, were to be removed from Part D and the commercial sector, we would actually reduce our list prices. 2:15:10 Giovanni Caforio: I would say that not only do we support all three elements that you mentioned, but I do believe those three elements together with the continued effort to develop a generic and biosimilar market would mean significant change, and would clearly alleviate the concerns that patients have today. 2:14:44 Jennifer Taubert: We are very supportive of all three elements that you outlined 2:15:52 Kenneth Frazier: We too support all three. 2:15:55 Albert Bourla: All three elements are transformational for our industry, will disrupt it. However, we do agree that these are the three things that need to be done and also I believe that will have significant meaningful results if we do. 2:16:10 Olivier Brandicourt: We support the three Senator, but we want to keep in mind at the end of the chain the patient has to benefit, so if rebates are removed it has to be to the benefit of patients. Sen. Thomas Carper (D-DE): Good, thanks. 2:18:10 Albert Bourla: 50% of the American people are in commercial plans and these rebate rules apply to Medicare. If the rules apply to all, definitely the list price will go down. 2:18:30 Albert Bourla: The list price is not irrelevant, it's very relevant for a lot of people because they have to pay list price during the deductible period. However if the rebate rule is applied, then they become irrelevant because the patients will not be paying the list price at the purchase point. 2:19:10 Sen. John Thune (R-SD): How would manufacturers respond if the rebate rule were finalized for government programs? I mean, what does that what does that mean for the commercial market? Albert Bourla: Senator, as I said before, all these proposals that they're discussing, [undistinguishable], eliminating the rebate rule, are transformational and will disrupt the way we do business. I don't know exactly how the system will evolve, and I really don't favor a bifurcated system. I would like to have a transparent single system across both parts. So we need to see how the whole thing will evolve. 2:25:26 Johnny Isakson (R-GA): Who sets the discount and who sets the rebate? 2:26:20 Richard Gonzalez: We negotiate with payers, so managed care and PBMs— Sen. Johnny Isakson (R-GA): You're a supplier though, so you have to go negotiate with the PBMs and those people, is that right? Richard Gonzalez: Correct, and they negotiate aggressively. Sen. Isakson: Is that pretty much true with everybody, that they're the major component between the end retail consumer price and the origin of the product? Richard Gonzalez: Yes, Senator. Sen. Isakson: Well, that seems like that's someplace we ought to focus, because that's where the distorted numbers come in. Johnson & Johnson, Janssen, in your testimony, you talked about your average list price of 8.1%, up, but an average net price change of only 4.6%. So while your gross went up 8.6, your net went down 4.6 In the same pricing period. How does that happen? If you're setting the price, how does it not go up on the bottom? Jennifer Taubert: Yeah, and in fact, in 2018, our net price actually declined 8.6%, so even more than that. The intermediaries in the system are very, very effective negotiators— Sen. Isakson: Tell me who the intermediaries are. Jennifer Taubert: Those would be the PBMs and the insurers. Sen. Isakson: …and the insurance companies? Jennifer Taubert: Right, and they set the formularies for patients. Sen. Isakson: And they're not the same. They're two different people? Jennifer Taubert: Yes, correct. 2:40:45 James Lankford (R-OK): All of you have mentioned the rebate issue has been a problem and that insurance companies and PBMs are very effective negotiators. Part of the challenge of this is, health insurance companies pay their PBM based on the quality of their negotiation skills, cutting a price off the list price. And so if a list price is higher and a rebate is higher, that also gives preference to them. So the difficulty is, as you raise list price, and the rebate gets larger, the insurance company gives that preference, making it harder for biosimilars. Am I tracking this correctly? 2:43:00 Albert Bourla: Here in the US, the penetration of biosimilars is much lower than in other places, but it is disproportional to different parts of the US healthcare system. For example, in open systems, systems where the decision maker it is a PBM, the one biosimilar we have has a market share of 5% in the US. In closed systems, in systems like Kaiser, for example, integrated healthcare systems where the one who decides has the whole cost of the healthcare system in its interest, we have 73%. 5% and 73% for the same product. I agree with what Mr. Fraser said that we need to create incentives, but I would add also that we need to break this rebate trap that creates significant disincentives for providers, and the healthcare system, and insurance companies. 3:19:25 Kenneth Frazier: If you went back a few years ago, when we negotiated to get our drugs on formulary, our goal was to have the lowest copay by patients. Today the goal is to pay into the supply chain the biggest rebate, and so that actually puts the patient at a disadvantage since they're the only ones that are paying a portion of the list price. The list price is actually working against the patient. 3:19:50 Sen. Steve Daines (R-MT): Why do we have a system today? Where you all are setting, I'll just say very, very high list prices, which is the starting point for negotiation. Why? Olivier Brandicourt: Senator, we're trying to get formulary position. With those list prices. High list price, high rebates. It's a preferred position. Unfortunately the preferred position doesn't automatically ensure affordability at the end. Kenneth C. Frazier: Senator, If you bring a product to the market with a low list price in this system, you get punished financially and you get no uptake because everyone in the supply chain makes money as a result of a higher list price. Drug Pricing in America: A Prescription for Change, Part III April 9, 2019 Senate Committee on Finance Witnesses: Steve Miller, MD, Former Executive Vice President and Chief Clinical Officer, Cigna Corporation Derica Rice, Former Executive Vice President and President, CVS Health and CVS Caremark William Fleming, Pharm.D., Segment President, Healthcare Services, Humana Inc. John Prince, Chief Executive Officer, OptumRx Mike Kolar, JD, Interim President & CEO, Senior Vice President and General Counsel, Prime Therapeutics LLC Clips Sen. Ron Wyden (D - OR): Pharmaceutical Benefit Managers first showed up decades ago, back when prescription drugs were being utilized more extensively. The PBMs told the insurance companies, “we're the ones who know drug pricing, we will handle the negotiations for you.” But there is little evidence that the pharmaceutical benefit managers have actually held down the prices in a meaningful way. In fact, most of the evidence shows just the opposite. Pharmaceutical Benefit Managers actually make more money when they pick a higher price drug over a lower price drug. Colleagues, let's remember that all the way through this discussion, benefit managers make more money when they pick a higher price drug over a lower price drug. The logic on this isn't exactly complicated, graduate-level economics. PBM profits are based on taking their slice of the prescription-drug pie. More expensive drugs means there's a bigger pie. When there's a bigger pie, [there are] bigger slices for the pharmaceutical benefit managers. 50:24 Mike Kolar: Rebates and the role they play have been key areas of focus in the drug cost debate. In our view, rebates are a powerful tool to offset high prices, which are set by pharmaceutical companies, and pharmaceutical companies alone. The fact that rebates are not offered on many of the highest cost drugs, and that studies show no correlation between prices and rebates underscore that rebates are a key to mitigating rather than causing high drug prices. We pass rebates through fully to our plans, and we believe our plans should be able to choose how to apply these rebates in ways that best serve their members and market needs by balancing premiums and cost sharing. 56:05 Sen. Chuck Grassley (R-IA): I'd like to talk about consolidation, including the recent integration of PBMs with insurance companies. Last year I wrote to the Justice Department on the issues, it reported that the three largest PBMs who are before us today now covers 71% of Medicaid, Medicare Part D enrollees and 86% of standalone Drug Plan enrollees. 57:45 Derica Rice: This is a highly competitive space. In addition to the three that you've pointed out here, CMS has noted there are over 60 PBMs across the US. Therefore, the competition, there's many options for the employers that are out there, government entities, as well as unions to choose from given their specific needs. 1:10:35 Sen. Debbie Stabenow (D-MI): So when we look at Express Scripts has 100 million Americans covered, CVS 90 million, OptumRx 65 million, Prime Therapeutics 27 million, Humana 21 million, and yet Americans still pay the highest prices in the world. Even though you are negotiating for millions of people. The VA has its own pharmacy benefit manager service, they negotiate for 9 million veterans, and they pay, on average, 40% less for the same drugs that the rest of the healthcare system pays for. Despite greater volume, you are unable to secure these kinds of low prices. With all due respect, you guys are pretty bad negotiators. Given the fact that the VA can get 40% less. And so I'd like to know from each of you why that's the case. Dr. Miller? Steve Miller [Former EVP and Chief Clinical Officer, Cigna Corporation]: Yes. Part of the equation is giving patients choice. At the VA, they actually limit their formulary more than any of us at this table do. So oftentimes, they'll have one beta blocker, one ace inhibitor. And so if it's going to get to that level of choice, then we could get better prices also. Sen. Stabenow: Let me jump in, in the interest of time. I know you create nationwide drug formularies, you have pre-authorization, you give preferred status to certain medications. So you don't use any of those tools that the VA is using? Because you do. Steve Miller: We definitely use those tools, but we also give people choice. It's crucial for both physicians and patients to have the choice of the products they want to be able to access. Many of our plans want us to have broad formularies and when you have more products, it means you move less market share. Sen. Stabenow: So basically you're saying a 40% premium gives them more choice. 1:24:30 Sherrod Brown (D-OH): If the administration's rebate rule were finalized as proposed, would you in some way be required to change the way you do business? Mike Kolar: Yes, Senator we would. John Prince: Yes. William Fleming: Yes. Derica Rice: Yes. Steve Miller: Yes. Sen. Brown: Thank you. 1:25:05 Sherrod Brown (D-OH): What percentage of prescriptions that you fill across Part D actually receive a rebate? Roughly what percentage? Mike Kolar: So Senator, approximately 8% of the prescriptions that we cover in Part D are associated with a rebate. Sen. Brown: Okay, Mr. Prince? John Prince: Senator, I don't know the exact number, I know our overall business is about 7%. Sen. Brown: Okay, thank you. William Fleming: About 7-8%. Derica Rice: Senator, I do not know the exact number but we pass through 100% of all rebates and discounts. Sen. Brown: [Grunt] Steve Miller: 90% of the prescriptions will be generic. Of the 10% that are branded, about two-thirds have rebates. So it's about seven-- Sen. Brown: 7-8% like the others. Okay. To recap, PBMs do not set drug prices. Forcing you to change the way you do business -- as the administration's rule would — will not change that fact. And while the rule might impact a small percentage of drugs and Part D that receive a rebate, it does nothing to lower costs, as your answer suggests, for the other 90% of prescriptions you fill. Most importantly, absolutely nothing in the proposed rule would require Secretary Azar's former employer or any other pharma company to lower the price of insulin or any other drug. It's important to establish that, so thank you for that. 1:41:40 Catherine Cortez Masto (D-NV): Let me ask you, Dr. Fleming, in your testimony, you say Humana's analysis of the rebate rule -- and we're talking about the administration's rebate rule now — found that approximately 17% of beneficiaries will see savings at the pharmacy counter as a result of this rule. Can you tell me a little bit more about who these people are? And what kind of conditions do they have? William Fleming: Senator, there will be a number of members who are taking brand drugs for which we get rebates and so it could vary all the way from the common chronic conditions, things like diabetes or hypertension or high cholesterol, all the way over to occasionally, not usually, but occasionally on the specialty drug side. When you think of some medications like treatments for rheumatoid arthritis, multiple sclerosis, places where there's competition. Cover Art Design by Only Child Imaginations Music Presented in This Episode Intro & Exit: Tired of Being Lied To by David Ippolito (found on Music Alley by mevio)

Kentucky Roll Call 07 - 15 - 22 by Kentucky Roll Call

Kentucky Roll Call 07 - 14 - 22 by Kentucky Roll Call

Kentucky Roll Call 07 - 13 - 22 by Kentucky Roll Call

Kentucky Roll Call 07 - 12 - 22 by Kentucky Roll Call

In this episode of the Church Security Roll Call, we're going to be discussing Engaging an Active Shooter. Weekly Show Notes: https://sheepdog-church-security.ck.page/weekly-notes (Only Available for One Week after Show Goes Live) - AND - Church Shooting Lessons Learned Download: https://sheepdog-church-security.ck.page/lessons-learned (Changes Monthly) - About our Company - Sheepdog Church Security is a Private Online Academy that provides both Distance and Self-Paced Learning to Safety Team Volunteers. Our training focuses on Routine Safety and Security Operations and Emergency Situations in Houses of Worship. Links below to learn more about us and the online training we offer! Official Website: https://sheepdogchurchsecurity.net/ Training Academy: https://sheepdog-church-security.thinkific.com/ - Sheepdog Supporters - Worship Security Association: https://worshipsecurity.vhx.tv/?code=sheepdog Protect My Ministry: https://www.protectmyministry.com/sheepdog-signup/ U.S. Law Shield: https://www.uslawshield.com/?affid=f83659a7-c044-11e9-a753-02fcb63ac2fe The Cornelius Project: https://thecorneliusproject.com/ - Follow us on Social Media - Facebook: https://www.facebook.com/Instructor.Moloney/ Linkedin: https://www.linkedin.com/company/sheepdog-church-security - Contacts for Business Inquiries - Contact Us: https://sheepdogchurchsecurity.net/contact-us/

Kentucky Roll Call 07 - 11 - 22 by Kentucky Roll Call

Kentucky Roll Call 07 - 08 - 22 by Kentucky Roll Call

Kentucky Roll Call 07 - 07 - 22 by Kentucky Roll Call

Kentucky Roll Call 07 - 06 - 22 by Kentucky Roll Call

Kentucky Roll Call 07 - 05 - 22 by Kentucky Roll Call

In this episode of the Church Security Roll Call, we're going to be discussing the 2017 First Baptist Church Shooting. Weekly Show Notes: https://sheepdog-church-security.ck.page/weekly-notes (Only Available for One Week after Show Goes Live) - AND - Church Shooting Lessons Learned Download: https://sheepdog-church-security.ck.page/lessons-learned (Changes Monthly) - About our Company - Sheepdog Church Security is a Private Online Academy that provides both Distance and Self-Paced Learning to Safety Team Volunteers. Our training focuses on Routine Safety and Security Operations and Emergency Situations in Houses of Worship. Links below to learn more about us and the online training we offer! Official Website: https://sheepdogchurchsecurity.net/ Training Academy: https://sheepdog-church-security.thinkific.com/ - Sheepdog Supporters - Worship Security Association: https://worshipsecurity.vhx.tv/?code=sheepdog Protect My Ministry: https://www.protectmyministry.com/sheepdog-signup/ U.S. Law Shield: https://www.uslawshield.com/?affid=f83659a7-c044-11e9-a753-02fcb63ac2fe The Cornelius Project: https://thecorneliusproject.com/ - Follow us on Social Media - Facebook: https://www.facebook.com/Instructor.Moloney/ Linkedin: https://www.linkedin.com/company/sheepdog-church-security - Contacts for Business Inquiries - Contact Us: https://sheepdogchurchsecurity.net/contact-us/

This is a bonus TP&R episode of Faithful Politics with our good friends Josh Burtram and Will Wright when they interviewed Amanda Carpenter of The Bulwark. Gaslighting is a tactic in which a person or entity, in order to gain more power, makes a victim question their reality. Enter former-President Trump. Over the last four years, America has been under the influence of a person who seemingly graduated from Gaslighting University with a Ph.D. in Alternative Facts. Whether Trump knows it or not, he is masterful in the art of gaslighting-jitsu. The guest this week may know a thing or two about being gaslit, as she has been the target of this Trump tactic, Amanda Carpenter joins Will and Josh to discuss her book, Gaslighting America: Why We Love It When Trump Lies to Us. They also discuss the future of the Republican Party, and how faith played a key role in her life during one of the most heinous acts perpetrated by the Trump campaign during 2016 primaries. Amanda Carpenter is a political commentator for CNN and author of GASLIGHTING AMERICA: Why We Love It When Trump Lies To Us. Prior to CNN she was the Communications Director for Senator Ted Cruz and previously served as Senior Communications Advisor and Speechwriter to Sen. Jim DeMint. For both senators, Carpenter crafted countless op-eds, speeches, talking points, briefing papers, jokes, press releases, tweets, Facebook posts, and other materials on a range of subjects before the United States Senate, including but not limited to economics, campaigns, healthcare, foreign affairs, and constitutional matters. Her work for them has been published in the Wall Street Journal, New York Times, Washington Post, and other outlets. Roll Call featured her in a 2014 front-page profile, "Ted Cruz's Twitter Torrent: Outspoken GOP Aide Takes on Own Party" calling her "Capitol Hill's most-followed staffer" on Twitter with more than 56,000 followers. In 2013, she led the creation of Cruz's viral #MakeDCListen speech and campaign that pollster Frank Luntz said produced "the best political sound-byte of 2013.” In 2011, she was named by the Washington Post as one of the "Top 10 Capitol Hill Staffers to Watch."  https://www.faithfulpoliticspodcast.com/ https://www.thebulwark.com/author/amanda-carpenter/ https://www.barnesandnoble.com/w/gaslighting-america-amanda-carpenter/1126314531?ean=9780062748003

Kentucky Roll Call 07 - 01 - 22 by Kentucky Roll Call

Kentucky Roll Call 06 - 30 - 22 by Kentucky Roll Call

Kentucky Roll Call 06 - 29 - 22 by Kentucky Roll Call

Kentucky Roll Call 06 - 28 - 22 by Kentucky Roll Call

Kentucky Roll Call 06 - 27 - 22 by Kentucky Roll Call

Our citizenship is first and foremost in the kingdom of God. Are you present and accounted for? Pastor Kevin Wallace encourages us from Romans 8 and reminds us of our role and calling.

Kentucky Roll Call 06 - 24 - 22 by Kentucky Roll Call

Kentucky Roll Call 06 - 23 - 22 by Kentucky Roll Call

Republicans who still haven't accepted that Joe Biden beat Donald Trump in 2020 are recruiting “a volunteer army” of poll watchers and poll workers for upcoming elections. For those who want transparent and fair elections, an influx of enthusiasm is theoretically a good thing. But if new poll workers and poll watchers have an agenda— chasing after fraud that didn't happen—can they hurt more than they help?   Guest: Alexandra Berzon, investigative reporter for the New York Times.  Guest hosted by Mary C. Curtis, columnist at Roll Call and host of its Equal Time podcast. If you enjoy this show, please consider signing up for Slate Plus. Slate Plus members get benefits like zero ads on any Slate podcast, bonus episodes of shows like Slow Burn and Dear Prudence—and you'll be supporting the work we do here on What Next. Sign up now at slate.com/whatnextplus to help support our work. Learn more about your ad choices. Visit megaphone.fm/adchoices